Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 October 2018 | Story UFS | Photo Varsity Sports
First ever netball final in Bloemfontein
The Kovsies will be aiming to lift the Varsity Netball trophy in front of their home supporters on Monday when they face Tuks in the final in the Callie Human Centre.

The netball team of the University of the Free State, once again after five years, earned themselves the right to stage a final in the Varsity Netball competition. The two-time champion, the Dream Team, qualified for the final after topping the log and then wiping the floor with the Maties on Monday (1 October 2018) in the semi-final. The score was 56-45. 

They will come up against Tuks in the Callie Human Centre on the UFS Bloemfontein Campus for the final tonight. The match will get underway at 18:45.

The team won the very first two years of the competition in 2013 and 2014. On both occasions, they had to play away from home – in 2013 against the Pukke in Potchefstroom and in 2014 against Tuks in Pretoria. 

It will be the fourth meeting between the Kovsies and Tuks within three months. The Free State students won the group fixture in August by 68-43, but Tuks had to do without a number of their star players. At the University Sport South Africa tournament in Bloemfontein during July, Tuks triumphed twice, winning the final by 48-30.

Apart from the winners’ medals, an award will be handed to the tournament’s top player. Centre Khanyisa Chawane is one of three finalists. The winner gets chosen through public votes.

Dream Team players have won the prize four of the five times. Ané Botha was crowned in 2013, Karla Pretorius in 2014 and 2015, and last year it was the turn of current Kovsie player, Khomotso Mamburu.

To vote for Chawane, click here hover your mouse over the like button and choose the heart emoticon. Voting is closing on 5 October and the winner will be announced after the final.

News Archive

New research informs improved treatment of brain inflammation
2017-10-13

Description: Sebolai and Ogundeji Tags: Microbiologist, Dr Adepemi Ogundeji,  

Dr Adepemi Ogundeji, researcher in the Department of Microbial,
Biochemical and Food Biotechnology at the
University of the Free State,
and Dr Olihile Sebolai,
her study leader from the same department.
Photo: Charl Devenish



Microbiologist Dr Adepemi Ogundeji has uncovered a new use for an old medicine that can potentially save lives and money. Under the guidance of her study leader, Dr Olihile Sebolai, Dr Ogundeji set out to fight a fungal disease caused by Cryptococcus neoformans. Drs Ogundeji and Sebolai are from the University of the Free State Department of Microbial, Biochemical and Food Biotechnology. 

Dr Ogundeji is passionate about education. “My aim will always be to transfer knowledge and skills in the microbiology field,” she said. “Dr Ogundeji’s study is celebrated in that it found a new purpose for existing medicines. An advantage of repositioning old medicines is by-passing clinical trials, which sometimes take 20 years, and the safety of such medicines is already known,” Dr Sebolai, explained.

Cryptococcus infections are difficult to control and often lead to brain inflammation. In layman’s terms: “Your brain is on fire”. People with HIV/Aids are especially vulnerable, surviving only about three months without treatment. Such patients may present with a Cryptococcus-emergent psychosis, and some with an out-of-control inflammatory condition when initiated on ARVs. 

Dr Ogundeji found that the clinically recommended dosage of aspirin (anti-inflammatory medicine), and quetiapine (anti-psychotic medicine) is sufficient to control the infection. Her exceptional work was readily published in some of the foremost journals in her field, namely, Antimicrobial Agents and Chemotherapy and Frontiers in Microbiology

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept